Inhibitors of acetylcholinesterase/cholinesterase, which represent the primary category of pharmacological agents currently employed in the therapeutic management of AD, are incapable of fully arresting the progression of Alzheimer’s disease. The gene discussed is ACHE; the disease is Alzheimer disease.